Galectin Therapeutics Announces Pricing of $9.8 Million Registered Direct Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall St set for lower open as Middle East clashes revive rate-hike speculation
- The Warsh pivot markets didn't expect
- Oil rises over 2% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
- GameStop posts higher income despite revenue drop in Q2 2026
- At least eight die, 18 missing after ferry capsizes off North Cyprus
- Manhunt underway after woman killed, several injured at Swiss rave shooting
- Aon close to acquiring USI Insurance from KKR in $17 billion deal, WSJ reports
- RedHill sells Talicia to Apotex for $18M upfront plus milestones
Galectin Therapeutics (GALT) Prices 4.76M Securities Purchase Agreement
November 20, 2015 9:04 AM ESTGalectin Therapeutics (NASDAQ: GALT) announced that it has entered into securities purchase agreement with certain institutional investors providing for the purchase and sale of 4,761,900 shares of common stock at a price of $2.06 per share and warrants to purchase up to 3,571,425 shares of common... More
